Therapy of systemic sclerosis
The treatment of the patient with Systemic Sclerosis has greatly improved in the last ten years, because of two kinds of achievements. A number of drugs have been demonstrated to be active in some disease manifestations like alveolitis, pulmonary hypertension and complicated Raynaud’s phenomenon. So...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2004-03-01
|
Series: | Reumatismo |
Online Access: | https://reumatismo.org/index.php/reuma/article/view/142 |
_version_ | 1818040926107336704 |
---|---|
author | G. Valentini |
author_facet | G. Valentini |
author_sort | G. Valentini |
collection | DOAJ |
description | The treatment of the patient with Systemic Sclerosis has greatly improved in the last ten years, because of two kinds of achievements. A number of drugs have been demonstrated to be active in some disease manifestations like alveolitis, pulmonary hypertension and complicated Raynaud’s phenomenon. Some of these drugs namely cyclophosphamide and iloprost await to be confirmed as disease modifying agents. The methological approach to be made in clinical trials has been defined allowing to correctly analyze the results of published trials and plan future ones. |
first_indexed | 2024-12-10T08:22:17Z |
format | Article |
id | doaj.art-5c9e1624de464d97b8b73813eef2220e |
institution | Directory Open Access Journal |
issn | 0048-7449 2240-2683 |
language | English |
last_indexed | 2024-12-10T08:22:17Z |
publishDate | 2004-03-01 |
publisher | PAGEPress Publications |
record_format | Article |
series | Reumatismo |
spelling | doaj.art-5c9e1624de464d97b8b73813eef2220e2022-12-22T01:56:19ZengPAGEPress PublicationsReumatismo0048-74492240-26832004-03-0156110.4081/reumatismo.2004.1Therapy of systemic sclerosisG. ValentiniThe treatment of the patient with Systemic Sclerosis has greatly improved in the last ten years, because of two kinds of achievements. A number of drugs have been demonstrated to be active in some disease manifestations like alveolitis, pulmonary hypertension and complicated Raynaud’s phenomenon. Some of these drugs namely cyclophosphamide and iloprost await to be confirmed as disease modifying agents. The methological approach to be made in clinical trials has been defined allowing to correctly analyze the results of published trials and plan future ones.https://reumatismo.org/index.php/reuma/article/view/142 |
spellingShingle | G. Valentini Therapy of systemic sclerosis Reumatismo |
title | Therapy of systemic sclerosis |
title_full | Therapy of systemic sclerosis |
title_fullStr | Therapy of systemic sclerosis |
title_full_unstemmed | Therapy of systemic sclerosis |
title_short | Therapy of systemic sclerosis |
title_sort | therapy of systemic sclerosis |
url | https://reumatismo.org/index.php/reuma/article/view/142 |
work_keys_str_mv | AT gvalentini therapyofsystemicsclerosis |